GeneTether Therapeutics (XCNQ:GTTX) Cash And Cash Equivalents : C$1.31 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is GeneTether Therapeutics Cash And Cash Equivalents?

GeneTether Therapeutics's quarterly cash and cash equivalents declined from Mar. 2024 (C$1.70 Mil) to Jun. 2024 (C$1.41 Mil) but then stayed the same from Jun. 2024 (C$1.41 Mil) to Sep. 2024 (C$1.31 Mil).

GeneTether Therapeutics's annual cash and cash equivalents increased from Dec. 2021 (C$0.23 Mil) to Dec. 2022 (C$2.44 Mil) but then declined from Dec. 2022 (C$2.44 Mil) to Dec. 2023 (C$1.83 Mil).

GeneTether Therapeutics Cash And Cash Equivalents Historical Data

The historical data trend for GeneTether Therapeutics's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneTether Therapeutics Cash And Cash Equivalents Chart

GeneTether Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

0.06

0.23

2.44

1.83

GeneTether Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash And Cash Equivalents	Get a 7-Day Free Trial											1.84	1.83	1.70	1.41	1.31

GeneTether Therapeutics Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

GeneTether Therapeutics (XCNQ:GTTX) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

GeneTether Therapeutics Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of GeneTether Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

GeneTether Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneTether Therapeutics Inc (XCNQ:GTTX) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

301-1665 Ellis Street, c/o Pushor Mitchell LLP, Kelowna, BC, CAN, X1X 1X1

Website

https://www.genetether.com

GeneTether Therapeutics Inc is a genetic medicines company focused on the development of high-efficiency precision gene editing for human therapeutics applications. It is engaged in creating gene-editing therapies based on the proprietary GeneTether platform. Further, it is focused on building a discovery pipeline for the treatment of rare, monogenic diseases of the kidney and the skin. Their platform is designed to increase the efficiency of genome editing technologies, including CRISPR-Cas, TALENs, and ZFNs.

GeneTether Therapeutics Headlines

No Headlines